Kynurenic acid, an aryl hydrocarbon receptor ligand, is elevated in serum of Zucker fatty rats

G Oxenkrug1,*, J Cornicelli2, M van der Hart3, J Roeser3, and P Summergrad1

1Department of Psychiatry, Tufts University School of Medicine, Boston, USA
2Charles River, Inc., USA
3Brains On-Line, S. San Francisco, USA

Abstract

Obesity is an increasingly urgent global problem and the molecular mechanisms of obesity are not fully understood. Dysregulation of the tryptophan (Trp) – kynurenine (Kyn) metabolic pathway (TKP) have been suggested as a mechanism of obesity and described in obese humans and in animal models of obesity. However, to the best of our knowledge, TKP metabolism has not been studied in leptin-receptor-deficient Zucker fatty rats (ZFR) (fa/fa), the best-known and most widely used rat model of obesity. We were interested to determine if there are any deviations of TKP in ZFR. Concentrations of major TKP metabolites were evaluated (HPLC- MS method) in serum of ZFR (fa/ff) and age-matched lean rats (FA/−). Concentrations of kynurenic acid (KYNA) were 50% higher in ZFR than in lean rats (p<0.004, Mann-Whitney two-tailed test). Anthranilic acid (AA) concentrations, while elevated by 33%, did not reach statistical significance (p<0.04, one-tailed test). Elevated KYNA serum concentrations might contribute to development of obesity via KYNA-induced activation of aryl hydrocarbon receptor. Present results warrant further studies of KYNA and AA in ZFR and other animal models of obesity.

Keywords

zucker fatty rats; kynurenic acid; aryl hydrocarbon receptor; obesity; metabolic syndrome

Introduction

Obesity is an increasingly urgent global problem. Molecular mechanisms of obesity have not been fully understood. Dysregulation of tryptophan (Trp) – kynurenine (Kyn) metabolic pathway (TKP) have been suggested to contribute to the development of obesity [1,2]. In mammals, TKP consists of three major phases: the initial phase in which conversion of Trp into KYN (via N-formylKYN) is catalyzed by inflammation-induced indoleamine-2,3-dioxygenase 1 (IDO) or stress-activated Trp-2,3-dioxygenase 2 (TDO); the intermediate phase characterized by Kyn conversion into 3-hydroxykynurenine (3-HK), kynurenic
KYNA and anthranilic (AA) acids; and final phase in which production of NAD$^+$ is initiated by 3-HK conversion into 3-hydroxyAA (Figure 1) [3]. KYNA and AA are the end-products of KTP in astrocytes and adipocytes because Kyn-3-monooxygenase (KMO), a riboflavin (vitamin B2)-dependent enzyme, that catalyzes Kyn conversion into 3-HK, is not expressed in these tissues [4,5].

Activation of TKP initial phase was reported in animal models of obesity [6,7] and in obese human subjects [8–10]. Recent studies found different patterns of TKP dysregulation in obese mice and in human obesity and concluded that these mouse models [high-fat diet induced-obesity and the leptin-deficiency (ob/ob)] are inappropriate for studies of TKP involvement in mechanisms of human obesity [11]. However, to the best of our knowledge, TKP metabolism has not been studied in leptin-receptor-deficient Zucker fatty rats (ZFR) (fa/fa), the best-known and most widely used rat model of obesity. We were interested to determine if there are any aberrations of TKP in ZFR by comparing serum concentrations of major TKP metabolites in ZFR (fa/fa) and lean rats (FA/-).

**Methods**

Serum samples (drawn after 5 hrs of fasting) from male ZFR (fa/fa) and lean (FA/-) rats (6 – 8 weeks of age) were provided by Charles River, Inc. and stored at -50°C until analysis. Trp, Kyn, KYNA, AA, 3-HK, and XA were analyzed by modified HPLC – MS method [12,13].

**Statistical analysis**

Results are presented as mean ± standard error (Trp and Kyn in μM and AA, KYNA, 3-HK and XA in nM). Statistical significance of differences between lean and ZFR (six rats in each group) was assessed by Mann-Whitney test.

**Results**

**Initial phase of TKP**

There were no difference of Trp and Kyn serum concentrations between ZFR and lean rats (Table 1).

Kyn:Trp ratio (an indirect marker of activity of enzymes catalyzing Trp conversion into Kyn) was not different between ZFR and lean rats (Table 1).

**Intermediate phase of TKP**

Serum concentrations of KYNA were elevated (by 50%) in ZFR (Table 1). There was a strong tendency to elevation of AA concentrations (by 33%). 3-HK concentrations did not differ between ZFR and lean rats.

**Final phase of TKP**

Concentrations of XA, a suggested diabetogenic 3-HK metabolite [17], did not differ between ZFR and lean rats.
Discussion

Present finding of elevated concentrations of serum KYNA (and, probably, of AA) in ZFR is important because, to the best of our knowledge, it is the first recognition of KTP dysregulation in ZFR; specifically, dysregulation of the intermediate phase of KTP in ZFR.

Our finding is in line with reported positive correlation of serum KYNA concentrations with BMI in obese subjects [4,14].

Elevation of serum KYNA concentrations might result from up-regulated KYNA biosynthesis in fat tissue, liver and monocyte/macrophages. Formation of KYNA and AA from Kyn is catalyzed by the vitamin B6 (PLP)-dependent enzymes KAT and Kynu, respectively (Figure 1). However, since KAT and Kynu are substrate-unsaturated enzymes, they are able to process additional amount of Kyn created by KMO inhibition. Thus, KYNA and AA were elevated in brain, liver and plasma of KMO(−/−) mice [15]. Furthermore, increased formation of KYNA and AA without activation of KAT and Kynu was observed in baboons and mice fed vitamin B2 (but not vitamin B6) deficient diets [16,17]. Therefore, KYNA elevation in serum of ZFR may be a consequence of KMO deficiency in fat tissue that does not express KMO genes [4]. On the other hand, KYNA might be synthesized by resident macrophages infiltrating omental adipose tissue, as this has been observed in women with obesity [4]. Therefore, KMO inhibition and/or Kynu activation may contribute to our observation of elevated serum KYNA (and AA) in ZFR. Identification of origin of serum KYNA elevation in ZFR needs further studies.

Functional implications of elevated KYNA in ZFR could depend on KYNA antagonism to N-methyl-d-aspartate (NMDAR) and alpha7 nicotinic acetylcholine receptors (α7nAChR) and activation of aryl hydrocarbon receptor (AHR).

AHR regulates xenobiotic-metabolizing enzymes such as aryl hydrocarbon hydroxylase (cytochrome P450) in humans, mice, rats and neonatal (but not adults) rabbits [18]. AHR over-activation promoted [19,20] while AHR deficiency protected mice from diet-induced obesity [21]. TKP metabolites (Kyn, KYNA and XA) are the endogenous human AHR ligands with potency comparable to exogenous ligands (e.g., 2,3,7,8-tetrachlorodibenzo-p-dioxin) [22,23]. Aryl hydrocarbon hydroxylase (cytochrome P450) is the major enzyme induced under control of the AHR [18]. Although we are not aware of AHR evaluation in ZFR, deficiency of AHR signaling pathways might be suggested by lower activity of hepatic microsomal aryl hydrocarbon hydroxylase and lower nuclear transcription rate of CYP2B1/2B2 mRNA in ZFR than in lean rats [24,25]. Up-regulated formation of KYNA, one of the strongest human hepatic AHR ligands [22], may represent an adaptive response aimed to overcome impairment of AHR signaling pathways in ZFR.

Besides interaction with AHR, elevated KYNA might affect ZFR via antagonism to NMDAR and α7nAChR. It was suggested that enhanced production of KYNA in astrocytes and increased extracellular KYNA inhibit dopamine (DA) release by blocking α7nAChR [26]. Decreased D2 receptor binding and elevated D2/3 receptor availability were reported in obesity [27,28]. Impaired DA function in ZFR was considered to be acquired, rather than
inherited, trait caused by circulating factors associated with obesity [29]. Our present data suggest that elevated serum KYNA might be one of such circulating factors.

Present results warrant further studies of KYNA and AA in the ZFR as a translatable model for assessing the impact of changing this metabolic pathway on obesity and its comorbid conditions.

Acknowledgments

GF Oxenkrug is a recipient of NIMH104810 grant.

References

1. Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci. 2010; 1199:1–14. [PubMed: 20633104]
2. Oxenkrug, G. 3-hydroxykynurenine acid and type 2 diabetes: implications for aging, obesity, depression, Parkinson’s disease and schizophrenia. In: Engin, A.; Engin, AB., editors. Tryptophan Metabolism: Implications for Biological Processes, Health and Diseases, Molecular and Integrative Toxicology. 2015, p. 173-195.
3. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13:465–477. [PubMed: 22678511]
4. Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, et al. The Kynurenine Pathway is Activated in Human Obesity and Shifted Toward Kynurenine Monoxygenase Activation. Obesity. 2015; 23:2066–2074. [PubMed: 26347385]
5. Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, et al. Characterization of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep. 2000; 5:108–111. [PubMed: 10939285]
6. Nacurotskaya V, Oxenkrug G, Vorobyova L, Summergrad P. Attenuation of high sucrose diet-induced insulin resistance in tryptophan 2,3-dioxygenase deficient Drosophila melanogaster vermilion mutants. Integr Obes Diabetes. 2015; 1:93–9526. [PubMed: 26191458]
7. Watts SWJ, Shaw S, Burnett R, Dorrance AM. Indoleamine 2,3-dioxygenase in periaortic fat: mechanisms of inhibition of contraction. Am J Physiol Heart Circ Physiol. 2011; 301:H1236–1247. [PubMed: 21841011]
8. Brandacher G, Hoeller E, Fuchs D, Weiss HG. Chronic immune activation underlies morbid obesity: isIDO a key player? Curr Drug Metab. 2007; 8:289–295. [PubMed: 17430117]
9. Mangge H, Summers KL, Meinitzer A, Zelzer S, Almer G, et al. Obesity-related dysregulation of the tryptophan-kynurenine metabolism: role of age and parameters of the metabolic syndrome. Obesity (Silver Spring). 2014; 22:195–201. [PubMed: 23625535]
10. Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M, et al. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. J Physiol Regul Integr Comp Physiol. 2012; 303:R135–R143. [PubMed: 22592557]
11. Poulain-Godefroy O, Eury E, Leloire A, Hennart B, Guillemin GJ, et al. Induction of TDO2 andIDO2 in Liver by High-Fat Feeding in Mice: Discrepancies with Human Obesity. J Biol Chem. 2013; 288:29–37. [PubMed: 26882470]
12. Oxenkrug G, van der Hart M, Roese R, Summergrad P. Anthranilic Acid: A Potential Biomarker and Treatment Target for Schizophrenia. Ann Psychiatry Ment Health. 2016:4.
13. Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, et al. Development of a series of aryl pyrimidine kynurenine monoxygenase inhibitors as potential therapeutic agents for the treatment of Huntington’s disease. J Med Chem. 2015; 58:1159–1183. [PubMed: 25590515]
14. Ho JE, Larson MG, Ghorbani A, Cheng S, Chen MH, et al. Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One. 2016; 11:e0148361. [PubMed: 26863521]
15. Giorgini F, Huang SY, Sathyasaikumar KV, Notarangelo FM, Thomas MA, et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem. 2013; 288:36554–36566. [PubMed: 24189070]

16. Verjee ZH. Tryptophan metabolism in baboons: effect of riboflavin and pyridoxine deficiency. Acta Vitaminol Enzymol. 1975; 29:198–201. [PubMed: 23659]

17. Charconnet-Harding F, Dalgliesh CE, Neuberger A. The relation between riboflavin and tryptophan metabolism, studied in the rat. Biochem J. 1953; 53:513–521. [PubMed: 13032103]

18. Kahl GF, Friederici DE, Bigelow SW, Okey AB, Nebert DW. Ontogenetic expression of regulatory and structural gene products associated with the Ah locus. Comparison of rat, mouse, rabbit and Sigmodon hispidus. Dev Pharmacol Ther. 1980; 1:137–162. [PubMed: 6100719]

19. Kerley-Hamilton JS, Trask HW, Ridgely CD, Dufour E, Ringelberg CS, et al. Obesity is mediated by differential aryl hydrocarbon receptor signaling in mice fed a Western diet. Environ Health Perspect. 2012; 120:1252–1259. [PubMed: 22609946]

20. Moyer BJ, Rojas IY, Kerley-Hamilton JS, Hazlett HF, Nemani KV, et al. Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. Toxicol Appl Pharmacol. 2016; 300:13–24. [PubMed: 27020609]

21. Xu CX, Wang C, Zhang ZM, Jaeger CD, Krager SL, et al. Aryl hydrocarbon receptor deficiency protects mice from diet-induced adiposity and metabolic disorders through increased energy expenditure. Int J Obes (Lond). 2015; 39:1300–9. [PubMed: 25907315]

22. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 2010; 115:89–97. [PubMed: 20106948]

23. Roberts EA, Golas CL, Okey AB. Ah receptor mediating induction of aryl hydrocarbon hydroxylase: detection in human lung by binding of 2,3,7,8-[3H] tetrachlorodibenzo-p-dioxin. Cancer Res. 1986; 46:3739–43. [PubMed: 3011254]

24. Huupponen R1, Pyykö K, Ala-Uotila S, Sotaniemi E. Activity of xenobiotic metabolizing liver enzymes in Zucker rats. Res Commun Chem Pathol Pharmacol. 1991; 72:307–314. [PubMed: 1947434]

25. Blouin RA, Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, et al. Cytochrome P450 2B enzyme (CYP2B) induction defect following phenobarbital treatment in the fa/fa Zucker rat: molecular characterization. Arch Biochem Biophys. 1993; 303:313–320. [PubMed: 8512318]

26. Okuno A1, Fukuwatari T, Shibata K. High tryptophan diet reduces extracellular dopamine release via kynurenic acid production in rat striatum. J Neurochem. 2011; 118:796–805. [PubMed: 21711351]

27. Davis LM, Michaelides M, Cheskin LJ, Moran TH, Aja S, et al. Bromocriptine Administration Reduces Hyperphagia and Adiposity and Differentially Affects Dopamine D2 Receptor and Transporter Binding in Leptin-Receptor-Deficient Zucker Rats and Rats with Diet-Induced Obesity. Neuroendocrinology. 2009; 89:152–162. [PubMed: 18984941]

28. Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, et al. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology. 2016

29. Cumming P, Maschner S, Riss PJ, Grill E, Pischetsrieder M, et al. Perturbed Development of Striatal Dopamine Transporters in Fatty Versus Lean Zucker Rats: a Follow-up Small Animal PET Study. Mol Imaging Biol. 2015; 17:521–528. [PubMed: 25537092]
Figure 1.
Three major phases of Tryptophan – Kynurenine metabolic pathway.
Abbreviations: Trp: tryptophan; Kyn: kynurenine; KYNA: kynurenic acid; 3HK: 3-hydroxykynurenine; AA: anthranilic acid; 3HAA: 3-hydroxyanthranilic acid; XA: xanthurenic acid (3-hydroxyKYNA); NAD⁺: nicotinamide adenine dinucleotide; KMO: kynurenine 3-monooxygenase; Kynu: kynureninase; KAT: kynurenine aminotransferase 2
Table 1
Kynurenines (serum) concentrations in Zucker fatty and lean rats.

| N=6 | Lean       | Obese     | P*  | P**  |
|-----|------------|-----------|-----|------|
| Trp (μM) | 133.60 ± 6.64 | 116.80 ± 4.14 | ns  |      |
| Kyn (μM)  | 1.89 ± 0.14    | 1.87 ± 0.16   | ns  |      |
| AA (nM)   | 60.08 ± 6.74    | 80.96 ± 15.55 | 0.08 | 0.04**|
| KYNA (nM) | 70.06 ± 2.77    | 105.05 ± 9.98 | 0.004* | 0.002**|
| 3HK (nM)  | 19.23 ± 0.98    | 20.57 ± 1.84  | ns  |      |
| XA (nM)   | 13.10 ± 1.50    | 14.21 ± 1.54  | ns  |      |
| Kyn/Trp   | 1.41 ± 0.09     | 1.60 ± 1.01   | ns  |      |

P* - Mann-Whitney; P* - two-tailed test; P** - one-tailed test.